Nicotinamide riboside for progressive multiple sclerosis
Part of Brain & nervous system, Immune system & allergy clinical trials.
This Phase 2 trial studies whether a vitamin-like supplement called nicotinamide riboside can slow or improve disability in progressive multiple sclerosis. It may help people whose symptoms have been steadily getting worse over the last 2 years.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of multiple sclerosis that is progressive (PPMS or SPMS), not relapsing MS
- You are between 18 and 65 years old
- Your nerve-function disability score (EDSS) is between 3 and 6.5
- You can do a 25-foot walking test (T25FW)
- Your MS disability has shown documented worsening within the last 24 months
- You can consent and you may be on a stable MS medicine (or none) for the past 3 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether cladribine (vs an inactive placebo pill) can slow disability worsening in people with a non-active, progressive form of multiple sclerosis. It may help by reducing the immune activity that can drive ongoing nerve damage, even without recent relapses.
This trial tests a new treatment using a patient's own immune cells, modified with vitamin D3, to try to calm the immune system and slow the progression of multiple sclerosis (MS) without causing major side effects. It is for people with progressive MS who have not had recent relapses.
This trial tests whether a daily supplement called nicotinamide riboside can help older adults who feel weak or frail to get stronger and more energetic. It lasts for several months and involves simple tests like a walking test and memory checks.
This study tests whether a daily supplement (nicotinamide riboside, a form of vitamin B3) can slow the progression of early Alzheimer's disease over two years. It is a randomized, double-blind trial, meaning half the participants will get the supplement and half will get a placebo (a pill with no active ingredient), and neither you nor the doctors will know which you are getting.
This trial tests whether a supplement called nicotinamide riboside (NR) can help people with rare forms of parkinsonism (PSP, MSA, or CBS). It is a double-blind study, meaning neither you nor the doctors will know if you are getting the real supplement or a placebo.
This trial tests a vitamin B3 supplement called nicotinamide riboside (NR) to see if it can help people with Smooth Muscle Dysfunction Syndrome (SMDS) who have a specific gene mutation. The goal is to improve blood flow problems in the brain (moyamoya-like disease) caused by the condition.
Hear when a new Multiple sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.